AstraZeneca announced on March 14th that it has signed a final agreement to acquire Amolyt Pharma, which has developed innovative therapeutic peptides for rare endocrine and metabolic diseases. AstraZeneca stated that this acquisition will strengthen its Alexion rare disease late stage product line and expand its bone metabolism franchise.
According to the terms of the agreement, AstraZeneca will acquire all outstanding shares of Amolyt Pharma for a total price of up to $1.05 billion, including a $800 million advance payment upon completion of the transaction and the right of Amolyt Pharma shareholders to receive an additional $250 million in contingent payments upon reaching specific regulatory milestones. The transaction is expected to be completed by the end of the third quarter of 2024.